Aspira Pathlab Intrinsic Value
Aspira Pathlab intrinsic value. Aspira Pathlab (ASPIRA) median intrinsic value is ₹35.74 from 9 valuation models (range ₹24–₹64), vs current price ₹119.15 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Read Aspira Pathlab dividend payments for the complete payout history and dividend yield track record.
ASPIRA Valuation Methods Summary — DCF, Graham Number & P/E
Aspira Pathlab intrinsic value across 9 models vs current price ₹119.15 — upside/downside and value range per method. For current market price and key ratios, visit Aspira Pathlab stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹35.74 | ₹28.59 - ₹42.89 | -70.0% | EPS: ₹2.64, Sector P/E: 12x |
| Book Value Method | asset | ₹23.83 | ₹21.45 - ₹26.21 | -80.0% | Book Value/Share: ₹12.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹35.74 | ₹32.17 - ₹39.31 | -70.0% | Revenue/Share: ₹24.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹47.66 | ₹42.89 - ₹52.43 | -60.0% | EBITDA: ₹4.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹47.66 | ₹38.13 - ₹57.19 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹35.74 | ₹32.17 - ₹39.31 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹35.74 | ₹32.17 - ₹39.31 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹64.00 | ₹57.60 - ₹70.40 | -46.3% | ROE: 33.3%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹35.74 | ₹32.17 - ₹39.31 | -70.0% | EPS: ₹2.64, BVPS: ₹12.00 |
ASPIRA Intrinsic Value vs Market Price — All Valuation Models
Aspira Pathlab fair value range ₹24–₹64 vs current market price ₹119.15 across 9 valuation models. Compare with Aspira Pathlab valuation methods to assess whether the stock is under or overvalued.
ASPIRA Intrinsic Value Analysis — Undervalued or Overvalued?
Aspira Pathlab median intrinsic value ₹35.74, current price ₹119.15 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of ASPIRA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Aspira Pathlab (ASPIRA) is ₹35.74 (median value). With the current market price of ₹119.15, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹23.83 to ₹64.00, indicating ₹23.83 - ₹64.00.
Is ASPIRA undervalued or overvalued?
Based on our multi-method analysis, Aspira Pathlab (ASPIRA) appears to be trading above calculated value by approximately 70.0%.
ASPIRA Financial Health — Key Ratios vs Industry Benchmarks
Aspira Pathlab financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.67 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 33.3% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 16.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.33x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
ASPIRA Cash Flow Quality — Operating & Free Cash Flow
Aspira Pathlab operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |